As both a positive and negative control for this analysis, we compared 10 lung adenocarcinoma samples with a MET exon 14 splice site mutation or deletion with all other lung adenocarcinoma samples to look for significant differential splicing between the two groups. Here, MET is linked to lung adenocarcinoma.